Epidemiology of recurrent pregnancy loss

Recurrent Pregnancy Loss: Causes, Controversies and Treatment

Volumn , Issue , 2007, Pages 1-13

  Christiansen, Ole B ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879787371     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (68)

1. World Health Organization. Recommended definitions; terminology and format for statistical tables related to the perinatal period. Acta Obstet Gynecol Scand 1977; 56:247–53
2. Farquharson R, Jauniaux E, Exalto N, on behalf of the ESHRE Special Interest Group for Early Pregnancy (SIGEP). Updated and revised nomenclature for the description of early pregnancy events. Hum Reprod 2005;20:3008–11.
3. Alberman E. The epidemiology of repeated abortion. In: Beard RW, Sharp F, eds. Early Pregnancy Loss: Mechanisms and Treatment. London: Springer-Verlag; 1988:9–17.
4. Warburton D, Strobino B. Recurrent spontaneous abortion. In: Bennet MJ, Edmonds DK, eds. Spontaneous and Recurrent Abortion. Oxford: Blackwell Scientific, 1987:193.
5. Stray-Pedersen B, Lorentzen-Styr AM. The prevalence of Toxoplasma antibodies among 11,736 pregnant women in Norway. Scand J Infect Dis 1979; 11:159–65.
6. Fertility and Employment 1979. The Danish Data Archives No. 0363, Odense University.
7. Cowchock FS, Smith JB. Predictors for live birth after unexplained spontaneous abortions: correlations between immunological test results, obstetric histories, and outcome of the next pregnancy without treatment. Am J Obstet Gynecol 1992; 167:1208–12.
8. Quenby SM, Farquharson RG. Predicting recurring miscarriage: What is important? Obstet Gynecol 1993; 82:132–8.
9. Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997; 12:387–9.
10. Christiansen OB, Pedersen B, Rosgaard A, et al. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod 2002; 17:809–16.
11. Jablonowska B, Selbing A, Palfi M, et al. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a doubleblind placebo-controlled study. Hum Reprod 1999; 14:838–41.
12. Carp HJ, Toder V, Torchinsky A, et al. Allogenic leukocyte immunization after five or more miscarriages. Recurrent Miscarriage Immunotherapy Trialists Group. Hum Reprod 1997; 12:250–5.
13. Nielsen HS, Christiansen OB. Prognostic impact of anticardiolipin antibodies in women with recurrent miscarriages negative for the lupus anticoagulant. Hum Reprod 2005; 20:1720–8.
14. Cauchi MN, Coulam CB, Cowchock S, et al. Predictive factors in recurrent spontameous abortion - a multicenter study. Am J Reprod Immunol 1995; 33:165–70.
15. Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register study. BMJ 2000; 320:1708–12.
16. Shakhar K, Ben-Eliyahu S, Loewenthal R, et al. Differences in number and activity of peripheral natural killer cells in primary versus secondary recurrent miscarriage. Fertil Steril 2003; 80:368–75.
17. Christiansen OB, Pedersen B, Nielsen HS, et al. Impact of the sex of first child on the prognosis in secondary recurrent miscarriage. Hum Reprod 2004; 19:2946–51.
18. Christiansen OB, Kolte AM, Nielsen HS. Secondary recurrent miscarriage - unique entity with repect to etiology and treatment. Curr Women’s Health Rev 2006; 2:119–24.
19. Christiansen OB, Mathiesen O, Husth M, et al. Placebo-controlled trial of active immunization with third party leukocytes in recurrent miscarriage. Acta Obstet Gynecol Scand 1994; 73:261–8.
20. Drakeley AJ, Quenby S, Farquharson RG. Mid-trimester loss; appraisal of a screening protocol. Hum Reprod 1998; 13:1471–9.
21. Cowchock FS, Smith JB, David S, et al. Paternal mononuclear cell immunization therapy for repeated miscarriage: predictive variables for pregnancy success. Am J Reprod Immunol 1990; 22:12–17.
22. Goldenberg RL, Mayberry SK, Copper RL, et al. Pregnancy outcome following a second-trimester loss. Obstet Gynecol 1993; 81:444–6.
23. Johnson PM, Chia KV, Risk JM, et al. Immunological and immuno- genetic investigation of recurrent spontaneous abortion. Dis Mark 1988; 6:163–171.
24. Alexander SA, Latinne D, Debruyere M, et al. Belgian experience with repeat immunization in recurrent spontaneous abortion. In: Beard RW, Sharp F, eds. Early Pregnancy Loss: Mechanisms and Treatment. London: Springer-Verlag, 1988:355–63.
25. Ho H, Gill TJ, Hsieh C, et al. The prevalence of recurrent spontaneous abortion, cancer, and congenital anomalies in the families of couples with recurrent spontaneous abortions or gestational trophoblastic tumors. Am J Obstet Gynecol 1991; 165:461–6.
26. Christiansen OB, Mathiesen O, Lauritsen JG, et al. Idiopathic recurrent spontaneous abortion. Evidence of a familial predisposition. Acta Obstet Gynecol Scand 1990; 69:597–601.
27. Emery AEH. Methodology in Medical Genetics. 2nd rev edn. Edinburgh; Churchill Livingstone, 1986.
28. Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 1996; 66:124–9.
29. Fedorcsak P, Storeng R, Dale PO, et al. Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstet Gynecol Scand 2000; 79:43–8.
30. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001; 16:2606–9.
31. Infante-Rivard C, Fernandez A, Gauthier R et al. Fetal loss associated with caffeine intake before and during pregnancy. JAMA 1993;270:2940–3.
32. Fenster L, Hubbard AE, Swan SH, et al. Caffeinated beverages, decaffeinated coffee, and spontaneous abortion. Epidemiology 1997; 8:515–23.
33. Giannelli M, Doyle P, Roman E, et al. The effect of caffeine consumption and nausea on the risk of miscarriage. Paediatr Perinat Epidemiol 2003; 17:316–23.
34. Rasch V. Cigarette, alcohol, and caffeine consumption: risk factors for spontaneous abortion. Acta Obstet Gynecol Scand 2003; 82:182–8.
35. Nielsen GL, Sorensen HT, Larsen H, et al. Risk of adverse outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001; 322:266–70.
36. Li DK, Liu L, Odouli R. Exposure to nonsteroidal anti-inflammarory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003; 327:368–72.
37. Brandt LP, Nielsen CV. Job stress and adverse outcome of pregnancy: a causal link or recall bias? Am J Epidemiol 1992; 35:302–11.
38. Florack EI, Zielhuis GA, Pellegrino JE, et al. Occupational physical activity and the occurence of spontaneous abortion. Int J Epidemiol 1993; 22:878–84.
39. Wang JX, Norman RJ, Wilcox AJ. Incidence of spontaneous abortion among pregnancies produced by assisted reproductive technology. Hum Reprod 2004; 19:272–7.
40. Daya S, Gunby J, and The Recurrent Miscarriage Trialists Group. The effectiveness of allogeneic leukocyte immunization in unexplained primary recurrent abortion. Am J Reprod Immunol 1994; 32: 294–302.
41. Creasy R. The cytogenetics of spontaneous abortion in humans. In: Beard RW, Sharp F, eds. Early Pregnancy Loss: Mechanisms and Treatment. London: Springer-Verlag, 1988:293–304.
42. Christiansen OB. A fresh look at the causes and treatment of recurrent miscarriage, especially its immunological aspects. Hum Reprod Update 1996; 2:271–93.
43. Pfeiffer KA, Fimmers R, Engels G, et al. The HLA-G genotype is potentially assoiated with idiopathic recurrent spontaneous abortion. Mol Hum Reprod 2001; 7:373–8.
44. Kruse C, Rosgaard A, Steffensen R, et al. Low serum level ofmannan-bind- ing lectin is a determinant for pregnancy outcome in women with recurrent spontaneous abortion.Am J Obstet Gynecol 2002; 187:1313–20.
45. Kruse C, Steffensen R, Varming K, et al. A study of HLA-DR and -DQ alleles in 588 patients and 562 controls confirms that HLA-DRB1*03 is associated with recurrent miscarriage. Hum Reprod 2004; 19: 1215–21.
46. Ogasawara M, Aoki K, Okada S, et al. Embryonic karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril 2000; 73:300.
47. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361:901–8.
48. Wramsby ML, Sten-Linder M, Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil Steril 2000; 74:987–91.
49. Rai R, Shlebak A, Cohen H, et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16:961–5.
50. Carp H, Salomon O, Seidman D, et al. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 2002; 17: 1633–7.
51. Roque H, Paidas MJ, Funai EF, et al. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91:290–5.
52. Tharapel AT, Tharapel SA, Bannerman RM. Recurrent pregnancy losses and chromosome abnormalities: a review. Br J Obstet Gynaecol 1985;92:899–914.
53. Franssen MTM, Korevaar JC, Leschot NJ, et al. Selective chromosome analysis in couples with two or more miscarriages: case-control study. BMJ 2005; 331:137–41.
54. Regan L. A prospective study of spontaneous abortion. In: Beard RW, Sharp F, eds. Early Pregnancy Loss. Mechanisms and Treatment. London: Springer-Verlag, 1988:23–37.
55. Coulam CB. Immunological tests in the evaluation of reproductive disorders: a critical review. Am J Obstet Gynecol 1992; 167:1844–51.
56. Sargent IL, Wilkins T, Redman CWG. Maternal immune responses to the fetus in early pregnancy and recurrent miscarriage. Lancet 1988; ii:1099–104.
57. Cowchock S, Bruce Smith J, Gocial B. Antibodies to phospholipids and nuclear antigens in patients with repeated abortions. Am J Obstet Gynecol 1986; 155:1002–10.
58. Rai R, Regan L, Clifford K, et al. Antiphospholipid antibodies and ß2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995:10:2001–5.
59. Wilson WA, Gharavi AE, Koike T, et al. International concensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:309–11.
60. Aoki K, Kajiura S, Matsumoto Y, et al. Preconceptional natural-killer activity as a predictor of miscarriage. Lancet 1995; 345:1340–2.
61. Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thro- mobophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006; 55:360–8.
62. Hviid TV, Christiansen OB. Linkage disequilibrium between human leukocyte antigen (HLA) class II and HLA-G - possible implications for human reproduction and autoimmune disease. Hum Immunol 2005; 66:688–99.
63. Jivraj S, Rai R, Underwood J, et al. Genetic thrombophilic mutations among couples with recurrent miscarriage. Hum Reprod 2006; 21: 1161–5.
64. Christiansen OB, Kruse C, Steffenson R, Varming K. HLA Class II, mannan-binding lectin (MBL) and recurrent miscarriage. Presented at the European Congress of Reproductive Immunology, Plzen, 2004, Abstract I30 in special issue of Am J Reprod Immunol.
65. Christiansen OB, Nybo-Andersen AM, Bosch E, et al. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril 2005; 83:821–39.
66. Christiansen OB, Andersen HH, Hojbjerre M, et al. Maternal HLA Class II allogenotypes are markers for the predisposition to fetal losses in families of women with unexplained recurrent fetal loss. Eur J Immunogenetics 1995; 22:323–34.
67. Christiansen OB, Riisom K, Lauritsen JG, et al. No increased histocompatibility antigen sharing in couples with idiopathic habitual abortions. Hum Reprod 1989; 4:160–2.
68. Ober C, van der Ven K. HLA and fertility. In: Hunt JB, ed. HLA and the Maternal-Fetal Relationship. Austin, TX:. RG Landers, 1996:133–56.